Oral CCR5 inhibitors to prevent HIV transmission: the new "morning-before pill"?
In a recent study by Matsuzawa and colleagues, Maraviroc, a CCR5 inhibitor, was used as pre-exposure prophylaxis against HIV-1 infection. The authors used an ex vivo model of HIV transmission to study the distribution and effectiveness of this HIV inhibitor in healthy volunteers. Strikingly, 3 days or more of oral administration of Maraviroc to healthy volunteers conferred protection against HIV infection to skin-derived Langerhans cells in the ex vivo system, suggesting Maraviroc as a useful candidate for pre-exposure prophylaxis in clinical trials.